Home Title

Transforming lives by delivering convenience through specialist expertise.

Transforming lives by delivering convenience through specialist expertise.

Transforming lives by delivering convenience through specialist expertise.

COVID 19

Following updated Government and Health Authority advice, to reduce the spread of COVID 19 and to reduce any risks to our employees, all employees across the Group are working from home, aside from those critical to the continued manufacture of our products. As part of our commitment to putting patients first, we are continually monitoring our supply chain and manufacturing capabilities and are confident that we will continue to be able to supply our allergy therapies and diagnostics. We continue to monitor the situation and are committed to maintain our mission of transforming allergy treatment.

+6% Revenue growth at constant (and 8% in actual terms)
19% Increase in pre-R&D operating profit to £16.9m (2020: £14.2m)
£40.3m Strong cash balance at 30 June 2021 (2020: £37.0m)
£2.9m Net profit for the year (2020: Net profit of £7.1m including cash settlement of £3.2m)

Our year in numbers

2021 was another record level of pre-R&D operating profit ahead of market expectations reflecting continued sales growth.

Annual Report 2021

Take your career to new heights

Our culture and values